HOT stock here trading significantly below cash balance , FDA acceptance expected within days with potential FDA decision in Q3 this year . Stock has very strong insider and institutional ownership .This stock is a potential 10 bagger potential play because of its super low valuation . Market Cap $39 Million Cash $65 Million Price 1.23 Shares Out 32 million Clearside Biomedical submits NDA for XIPERE in macular edema associated with uveitis http://www.biotuesdays.com/briefs/2...pere-in-macular-edema-associated-with-uveitis Uveitis is a set of ocular inflammatory conditions and is one of the leading causes of vision loss, affecting about 350,000 patients in the U.S. and more than one million worldwide. If approved by the FDA, XIPERE would be the first therapy for macular edema associated with uveitis. The uveitis market is expected to grow to nearly $550-million in the U.S. and more than $1-billion globally by 2024. Product Pipeline http://www.clearsidebio.com/programs.htm#pipeline Largest shareholders : Wellington Management Co. LLP 4 397 523 Hatteras Venture Partners 3 466 394 Bradford T. Whitmore, MBA 3 200 000 BlackRock Fund Advisors 1 764 105 The Vanguard Group, Inc. 1 198 301 Sphera Funds Management Ltd. 1 154 690 Rock Springs Capital Management LP 975 000 Millennium Management LLC 899 428 AWM Investment Co., Inc. 875 126 Sofinnova Ventures, Inc. 606 914
still a mega buying opportunity at this 39 million valuation which is wayy below their cash balance of $65 million .GL Presentation January 2019 http://ir.clearsidebio.com/static-files/7edc337d-df24-4e66-b1f8-97ff01b3c9a0 Clearside Biomedical names industry veteran, Dr. Thomas Ciulla, as CMO http://www.biotuesdays.com/briefs/2...ames-industry-veteran-dr-thomas-ciulla-as-cmo Dr. Ciulla has more than 27 years of clinical practice, academic and executive management experience within the global ophthalmic industry. Prior to joining Clearside, he was VP of ophthalmic strategy at Spark Therapeutics, where he led the medical strategy to support development and commercialization of Luxturna, the first FDA-approved gene therapy for a genetic disease. Before launching his executive management career, Dr. Ciulla co-directed the retina service and ocular angiogenesis research laboratory at Indiana University School of Medicine, the largest U.S. medical school. He also serves on the board of Midwest Eye Institute and is an active member of the Association for Research in Vision and Ophthalmology, Macula and Retina Societies, American Society of Retina Specialists, and the American Academy of Ophthalmology. Dr. Ciulla also has held numerous leadership roles in more than 100 national clinical trials, including CATT and registration trials for nearly all retinal therapeutics currently approved by the FDA.
Looks like another good day ahead ... shareholders should put a high sell limit order like $5 so your shares will not be available on the market to short and the more positive effect is that it helps the stock to make bigger jumps it works especially on low floats stocks like CLSD .Thank you https://www.contracts-for-difference.com/Borrowing-lending-shares.html Q:What can you do to prevent your shares holdings from being shorted? A: Now what can the average personal investor do to stop their own shares being shorted, as believe me your own broker, if approached, WILL sell your own shares that they hold on your behalf as a nominee account. There are two things you can do, the first is to certificate them but this is not obviously to everyone’s advantage but the alternative solution is simple. All you do is to phone your broker and put an order in saying that you wish to place your shares for sale at, for arguments sake, double today’s price. As they are ‘on order’ they cannot be lent out by your broker and in turn you are reducing the amount of ‘free shares’ out there that can be used for shorting purposes. And don’t forget to move your limit order up when the price starts to recover, then, that way your shares can’t be shorted – not much but helps . Although an individual personal investor will not normally have enough shares to halt a concerted shorting attack, if a large number of holders did this it would reduce the overall amount of shares that they could get their hands on. In my opinion well worth doing if not only for the knowledge that your own shares cannot and will not be used in a short attack against the very share that you own.
Clearside Biomedical, Inc. (CLSD): Outperform Candidate With 330.88% Upside Potential Clearside Biomedical, Inc. is maintained at an average outperform rating by 8 stock analysts, and there are at least 2.8% of shares outstanding that are currently legally short sold. The shares went up by 15.25% in value last month. Year-to-date it jumped 27.1%. Analysts are turning out to be more optimistic than before, with 5 of analysts who cover Clearside Biomedical, Inc. (NASDAQ:CLSD) advice adding it to buy candidate list. Wall Street experts also assign a $5.86 price target on Clearside Biomedical, Inc., pointing towards a 330.88% rally from current levels. The stock is trading for about -91.13% less than its 52-week high. https://www.postanalyst.com/2019/02...dical-inc-clsd-golden-entertainment-inc-gden/
GREAT News out ..NDA accepted by FDA https://thefly.com/landingPageNews....on-of-FDA-acceptance-of-NDA-filing-for-Xipere
